Untreated and minimally pretreated solid tumor patients received alternating sequences of taxol and cisplatin. Sequential dose escalation of each agent using taxol doses of 110 or 135 mg/m2 and cisplatin doses of 50 or 75 mg/m2 resulted in four dosage permutations that induced grades 3 and 4 neutropenia in 72% to 84% and 50% to 53% of courses, respectively. Neutropenia was brief, and hospitalization for neutropenia and fever was required in 13% to 24% of courses. However, further escalation of taxol to 170 or 200 mg/m2 induced grade 4 neutropenia in 79% to 82% of courses. At the highest taxol-cisplatin dose level (200 mg/m2 to 75 mg/m2), the mean neutrophil count nadir was 98/microL, and hospitalization for neutropenia and fever was required in 64% of courses. The sequence of cisplatin before taxol, which has less antitumor activity in vitro, induced more profound neutropenia than the alternate sequence. Pharmacologic studies indicated that this difference was probably due to 25% lower taxol clearance rates when cisplatin preceded taxol. Although neurotoxicity was initially thought to be a potentially serious effect of the combination, mild to modest neurotoxicity occurred in only 27% of patients. Adverse effects also included myalgias, alopecia, vomiting, diarrhea, bradycardia, and asymptomatic ventricular tachycardia. Objective responses were noted in melanoma, as well as non-small-cell lung, ovarian, breast, head and neck, colon, and pancreatic carcinomas. Based on these results, the sequence of taxol before cisplatin at doses of 135 and 75 mg/m2, respectively, is recommended for phase II/III trials, with escalation of taxol to 170 mg/m2 if treatment is well tolerated.

After completing the course, the reader will be able to:1. Educate community oncologists about the promise of anti-CTLA-4 monoclonal antibodies for the treatment of advanced cancer. 2. Suggest that CTLA-4 blockade overcomes barriers to effective immunotherapy for cancer. 3. Describe the rational design and clinical development strategy taken with the CTLA-4 antagonist tremelimumab.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACT

Antibodies against a conserved RNA-binding protein, the Ro 60-kDa autoantigen, occur in 24 -60% of all patients with systemic lupus erythematosus. Anti-Ro antibodies are correlated with photosensitivity and cutaneous lesions in these patients and with neonatal lupus, a syndrome in which mothers with anti-Ro antibodies give birth to children with complete congenital heart block and photosensitive skin lesions. In higher eukaryotes, the Ro protein binds small RNAs of unknown function known as Y RNAs. Because the Ro protein also binds misfolded 5S rRNA precursors, it is proposed to function in a quality-control pathway for ribosome biogenesis. Consistent with a role in the recognition or repair of intracellular damage, an orthologue of Ro in the radiation-resistant eubacterium Deinococcus radiodurans contributes to survival of this bacterium after UV irradiation. Here, we show that mice lacking the Ro protein develop an autoimmune syndrome characterized by anti-ribosome antibodies, anti-chromatin antibodies, and glomerulonephritis. Moreover, in one strain background, Ro ؊/؊ mice display increased sensitivity to irradiation with UV light. Thus, one function of this major human autoantigen may be to protect against autoantibody development, possibly by sequestering defective ribonucleoproteins from immune surveillance. Furthermore, the finding that mice lacking the Ro protein are photosensitive suggests that loss of Ro function could contribute to the photosensitivity associated with anti-Ro antibodies in humans.

An Allen correction and a polychromatic analysis are about equally effective in minimizing effects of interference by bilirubin and triglyceride turbidity in the direct spectrophotometry of serum hemoglobin: interference from bilirubin is nearly eliminated, that from turbidity substantially decreased. The limit of detectability of hemoglobin is 8 mg/L in the presence of a moderate concentration of bilirubin. A change in hemoglobin concentration as small as 16 mg/L can be detected in serum having a concentration near the upper limit of the reference interval, i.e., at the medical decision level. The polychromatic formula gives concentration estimates approximately 5% greater than those of the Allen correction. The formula for the Allen correction is hemoglobin (mg/L) = 1.68 mA415 - 0.84 mA380 - 0.84 mA450 . That for the polychromatic analysis is hemoglobin (mg/L) = 1.65 mA415 - 0.93 mA380 - 0.73 mA470 .